Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review

Bosch, Alessandra; Uleryk, Elizabeth; Avila, Laura

doi:10.1016/j.rpth.2023.100064

Cited by 5 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Підвищений вміст факторів VIII, IX і XI у плазмі пов'язаний з ВТЕ [75]. Ці фактори беруть участь у фазі поширення коагуляційного каскаду.…”

Section: роль активації коагуляції при тгвunclassified

Pathophysiological Mechanisms of Deep Vein Thrombosis

Chooklin,

Chuklin

2023

Fiziol Zh

View full text Add to dashboard Cite

Deep venous thrombosis is a frequent multifactorial disease and most of the time is triggered by the interaction between acquired risk factors, particularly immobility, and hereditary risk factors such as thrombophilias. The mechanisms underlying deep venous thrombosis are not fully elucidated; however, in recent years the role of venous flow, endothelium, platelets, leukocytes, and the interaction between inflammation and hemostasis has been determined. Alteration of venous blood flow produces endothelial activation, favoring the adhesion of platelets and leukocytes, which, through tissue factor expression and neutrophil extracellular traps formation, contribute to the activation of coagulation, trapping more cells, such as red blood cells, monocytes, eosinophils, lymphocytes. The coagulation factor XI-driven propagation phase of blood coagulation plays a major role in venous thrombus growth, but a minor role in hemostasis. In this work, the main mechanisms involved in the pathophysiology of deep vein thrombosis are described.

show abstract

Section: роль активації коагуляції при тгвunclassified

Pathophysiological Mechanisms of Deep Vein Thrombosis

Chooklin,

Chuklin

2023

Fiziol Zh

View full text Add to dashboard Cite

show abstract

“…6 A recent systematic review regarding FVIII, FIX, and FXI as potential predictors of recurrent VTE, which involve 19 studies published until 2022, showed, however, conflicting data on a predictive role of FVIII and FXI and failed to find any role of FIX so far. 7 Statins, the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, have several additional effects, including antithrombotic actions, which have been largely considered as independent of cholesterol-lowering actions. Statins have been reported to downregulate tissue factor expression and increase protein C activation, with the subsequent reduction of thrombin generation and favorably altered fibrin clot properties.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of Three-Day Atorvastatin Administration on Coagulation Factors in Patients With Prior Venous Thromboembolism and Healthy Subjects: A Preliminary Study

Stępień,

Żółciński,

Ząbczyk

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Statins exert antithrombotic effects, which might contribute to reduced risk of venous thromboembolism (VTE). Rosuvastatin 20 mg/d administered for 4 weeks has been reported to decrease coagulation factors (F) VII, FVIII, and FXI in VTE patients. Moreover, in accordance with recent registry data in non-VTE subjects statins usage was associated with lower FXI. We investigated whether three doses of a statin decrease coagulation factors activity and if such changes can alter fibrin clot properties in VTE patients and healthy subjects. We enrolled 28 consecutive first-ever prior VTE patients after 6 months anticoagulation and 25 healthy controls well-matched for demographics and lipid profiles (aged 44 [IQR 34-51] years) in an interventional nonrandomized study. Before and after three doses of atorvastatin 40 mg/d, activity of FVII, FVIII, FIX, and FXI was measured, along with fibrin clot properties, including permeability (Ks) and clot lysis using 3 various assays. After 3-day statin administration we observed the decrease of FVII (by 6.2%, P= P=0.046) and FXI (by 8.6%, P=0.044), irrespectively of LDL-C reduction (by 24%, P<0.001), while other coagulation factors remained unaltered. Reduction of FVII and FXI activity was inversely correlated with Ks alterations (R=-0.292, P=0.034 and R=-0.335, P=0.014, respectively). After adjustment for age, studied group and fibrinogen level, the reduction of FXI was independently associated with an increase of fibrin clot permeability (B=-0.084, P=0.027). In conclusion, a three-day 40 mg atorvastatin administration is sufficient to reduce FVII and FXI activity in our pilot study, which is associated with favorable fibrin clot properties modification.

show abstract

“…The proportion mediated indicated that FVIII reduced the total effect by 2%. When adding blood group as a covariate in exploratory analysis, the results of the mediation analysis did not change (data not shown) 1 2 3 4 5 6 7 8 9 .…”

mentioning

confidence: 97%

The mediating role of coagulation factor VIII in the effect of chronic inflammation on recurrent thrombotic events in children with non-central line deep vein thrombosis

Bosch,

Jarvis Brunsvig,

Brandao

et al. 2024

Hämostaseologie

View full text Add to dashboard Cite

Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review

Cited by 5 publications

References 63 publications

Pathophysiological Mechanisms of Deep Vein Thrombosis

Pathophysiological Mechanisms of Deep Vein Thrombosis

Effect of Three-Day Atorvastatin Administration on Coagulation Factors in Patients With Prior Venous Thromboembolism and Healthy Subjects: A Preliminary Study

The mediating role of coagulation factor VIII in the effect of chronic inflammation on recurrent thrombotic events in children with non-central line deep vein thrombosis

Contact Info

Product

Resources

About